Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Eosinophilia & Hypereosinophilia Diagnosis & Treatment Tips

Thomas R. Collins  |  Issue: June 2018  |  June 21, 2018

Dr. Bochner has co-authored a paper on when to consider specific tests in patients with hypereosinophilia syndrome (HES) and suggested it as a guide.1

“In many of these conditions, one of the deadliest complications is endomyocardial involvement—that’s why troponin is on this list of potential tests to order. Some of the worst patients I’ve seen had CBCs [complete blood counts] without a differential in the emergency [department], had chest pain, had normal coronary arteries by catheterization and turned out to have HES with cardiac involvement. The troponin was not due to ischemia, but instead was due to eosinophils infiltrating the myocardium,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In recent years, several anti-eosinophil therapies have been approved for the treatment of eosinophilic asthma, including mepolizumab, resluzumab and benralizumab. Others in development include dexpramipexole, an oral agent related to the existing drug pramipexole, a dopamine agonist that was inadvertently found to reduce eosinophil numbers and anti-Siglec 8, a monoclonal antibody that targets eosinophils and mast cells. Although none of these are approved by the U.S. Food & Drug Administration for HES treatment, published data suggest some agents have efficacy, Dr. Bochner said.

He said answers to some key questions could help improve treatment of hyper­eosinophilia-related disorders.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“I wish we had better biomarkers for assessing disease activity,” he said. “We all follow the eosinophil counts and that’s about as good as it gets. I wish we had less invasive ways of imaging eosinophilic inflammation instead of having to do biopsies. We still don’t understand what causes eosinophil activation in these disorders, or what perpetuates it.”

Note: Dr. Bochner is a consultant for GlaxoSmithKline, AstraZeneca and Teva Pharmaceutical Industries, which develop drugs for hypereosinophilia disorders, and he’s a co-holder of Siglec-8 patents, entitling him to a share of future royalties on products protected by those patents.


Thomas R. Collins is a freelance writer living in South Florida.

References

  1. Khoury P, Bochner BS. Consultation for elevated blood eosinophils: Clinical presentations, high value diagnostic tests, and treatment options. JACI-In Practice. 2018. In press.

Page: 1 2 | Single Page
Share: 

Filed under:Vasculitis Tagged with:Eosinophiliahypereosinophilianeutropenia

Related Articles
    Kamolrat/SHUTTERSTOCK.COM

    Eosinophilia: A Diagnostic Evaluation Guide for Rheumatologists

    June 15, 2015

    Clinical Vignette A 45-year-old woman with long-standing asthma and chronic sinusitis has new-onset peripheral neuropathy, arthralgias, fatigue, progressive dyspnea and a nonproductive cough. She has never smoked and has no environmental exposures. Her medications include an albuterol metered-dose inhaler (which she uses daily); an inhaled corticosteroid, montelukast; and ibuprofen (which she takes occasionally). She is…

    Case Report: Skin-Deep Eosinophils

    Case Report: Skin-Deep Eosinophils

    May 17, 2018

    Eosinophilia is usually defined as an eosinophil count of more than 500/microL in peripheral blood.1 An eosinophil count of more than 1,500 is referred to as hypereosinophilia (HE); hypereosinophilic syndrome (HES) is defined as HE associated with organ dysfunction attributable to eosinophilia.2 Eosinophilia can occur due to infectious, malignancy, autoimmune or allergic etiologies. However, a…

    Eosinophilic Gastroenteritis & Eosinophilic Ascites Associated with RA

    June 17, 2019

    Eosinophilic gastroenteritis (EGE) is a rare condition caused by eosinophilic infiltration of the gastrointestinal (GI) tract. The condition is subdivided into the GI layers it affects: mucosal, muscular and subserosal.1 EGE usually presents with non-specific GI symptoms, such as impaired motility, intestinal obstruction and, rarely, ascites.2 Below, we report a rare case of EGE leading…

    The Latest on Eosinophilic Granulomatosis with Polyangiitis

    July 19, 2018

    The past five years have been busier than usual for the Churg-Strauss syndrome. It was renamed eosinophilic granulomatosis with polyangiitis (EGPA).1 Longitudinal cohorts totaling 484 patients—approximately as many as all previous series combined—were described.2,3 A proposal was advanced to remove and rename a subset in which vasculitis may not be present.4 And shortly after the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences